NDATOPICALLOTION
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
6/8 — Strong
ARAZLO (tazarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2019.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARAZLO (tazarotene) is a topical retinoid lotion approved in December 2019 for acne and psoriasis indications. It works by modulating retinoid receptors to reduce follicular cohesion and increase epithelial cell turnover. The drug is currently in peak commercial lifecycle with stable market presence.
$0.29MPart D
PeakStable
11.9 years to LOEModest Medicare utilization with 526 Part D claims indicates stable but niche positioning; brand team likely focused on maintaining dermatology channel relationships rather than growth acceleration.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
Started Feb 2014
66 enrolled
Nail Psoriasis
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
Started Jun 2010
59 enrolled
Acne Vulgaris
Worked on ARAZLO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.